References
- Balint GA. 2001. Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 90:261–265.
- Crawley J, Nahlen B. 2004. Prevention and treatment of malaria in young African children. Semin Pediatr Infect Dis. Elsevier.169–180.
- Dondorp AM, Day NP. 2007. The treatment of severe malaria. Trans R Soc Trop Med Hyg. 101:633–634.
- Dutta G, Tripathi R. 2003. New Antimalarial Drug Development in India: Arteether oz/[5-a Blood Schizontocide. Proc Indian natn Sci Acad. B69 No 861–870.
- Ferone R. 1977. Folate metabolism in malaria. Bull World Health Organ. 55:291.
- Gkrania-Klotsas E, Lever AM. 2007. An update on malaria prevention, diagnosis and treatment for the returning traveller. Blood Rev. 21:73–87.
- Klayman DL. 1985. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 228:1049–1055.
- Krishna AK, Flanagan DR. 1989. Micellar solubilization of a new antimalarial drug, β-arteether. J Pharma Sci. 78:574–576.
- Oshaghi M, Vatandoost H, Gorouhi A, Abai M, Madjidpour A, Arshi S, et al. 2011. Anopheline species composition in borderline of Iran–Azerbaijan. Acta Trop. 119:44–49.
- Pople PV, Singh KK. 2011. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus. Eur J Pharm Biopharm. 79:82–94.
- Vohra T, Kaur I, Heer H, Murthy RR. 2013. Nanolipid carrier-based thermoreversible gel for localized delivery of docetaxel to breast cancer. Cancer Nanotechnol. 4:1–12.
- Westesen K, Bunjes H, Koch M. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 48:223–236.